RESUMEN
Guidelines for describing cancer chemotherapy regimens in all aspects of drug development, including treatment protocols, order forms, and product labels, are proposed. To complement the approaches to reducing medication errors that have been recommended by ASHP and others, pharmacists at the National Institutes of Health and the National Cancer Institute, with the input of oncology pharmacists from diverse areas of practice, developed guidelines for expressing chemotherapy dosage schedules and treatment regimens. The guidelines present standards that are broadly applicable and can be adopted by other institutions. Clear and unambiguous expression of all medication orders and consistency of treatment descriptions are suggested. Written treatment plans and orders should contain enough information to allow health care providers from diverse disciplines to compare them with published treatment descriptions and investigational protocols and must therefore include planned dosages and schedules expressed in patient-specific units. In general, drug dosages should be expressed as the amount of drug administered from a single container. When ordering drugs that are part of complex or combination-drug regimens, prescribers should write as many of the orders at one time as is possible, so that continuity might be preserved. Standard rules are proposed for describing chemotherapy regimens.
Asunto(s)
Antineoplásicos/administración & dosificación , Esquema de Medicación , Etiquetado de Medicamentos/normas , Guías de Práctica Clínica como Asunto , Terminología como Asunto , American Medical Association , American Nurses' Association , Educación en Farmacia/normas , Control de Formularios y Registros/normas , Humanos , Errores de Medicación , National Institutes of Health (U.S.) , Sociedades Farmacéuticas , Estados UnidosRESUMEN
BACKGROUND: The National Cancer Institute (NCI)-sponsored clinical trials cooperative groups place more than 25 000 American patients in treatment trials every year. Equal access and proportional representation of all races/ethnicities is desired. PURPOSE: Our objectives were to evaluate the inclusion of African-Americans, Hispanics, and non-Hispanic whites in NCI-sponsored treatment trials and to determine if there is proportional racial/ethnic representation. METHODS: During the period of January 1, 1991, through June 30, 1994, 99 495 cancer patients were enrolled in clinical trials and declared themselves as non-Hispanic black, non-Hispanic white, or Hispanic (of any race). In the analysis, participants in NCI treatment trials were subdivided into three age groups: birth to 19 years, 20-49 years, and 50 or more years. The racial/ethnic composition of each of these age groups was compared with the racial/ethnic makeup of the American population with cancer. Estimates of the number of incident cancer cases per year were made for each racial/ethnic group within each age group using data from the Surveillance, Epidemiology, and End Results (SEER) Program and the 1990 Census. The percentage of all cancer patients who were in each racial/ethnic group were compared with the population that entered clinical trials. Comparisons are also made separately for patients with leukemia and breast, colorectal, lung, and prostate cancers. RESULTS: Among patients 0-19 years old, 20-49 years old, and 50 years old or older there is relatively proportional representation of non-Hispanic blacks, Hispanics, and non-Hispanic whites in trials. It is noted that more than 70% of cancer patients aged 0-19 years are estimated to enter cooperative group clinical trials compared with 4.0% of cancer patients aged 20-49 years and 1.5% of patients aged 50 years or older. CONCLUSIONS: Accrual of American cancer patients to NCI-sponsored treatment trials generally parallels the incident burden of disease among non-Hispanic African-Americans, Hispanics, and non-Hispanic whites. IMPLICATIONS: This study shows that the NCI clinical trials are, as a whole, racially/ethnically representative of the American population and suggests that there is equal access to NCI clinical trials.
Asunto(s)
Negro o Afroamericano/estadística & datos numéricos , Ensayos Clínicos como Asunto/estadística & datos numéricos , Hispánicos o Latinos/estadística & datos numéricos , Neoplasias/terapia , Población Blanca/estadística & datos numéricos , Humanos , National Institutes of Health (U.S.) , Estados UnidosRESUMEN
A decentralized emergency medicine clinical pharmacy program was initiated and has operated now for over 1 year. The program attempted to answer two questions: is there a viable clinical pharmacy role in emergency medicine, and could staff pharmacists successfully function in such a role without formal clinical training and experience? Initial primary objectives were to provide an on-the-spot pharmaceutical consultation service and to initiate new or expanded traditional pharmacy support to staff and patients. A secondary objective was to provide expanded outpatient prescription service to emergency room patients.